ProCE Banner Activity

Biomarkers for Risk Stratification and Treatment Selection for Patients With MCL

Slideset Download
Download these slides from a live symposium to gain more insight into the management of MCL.

Released: June 05, 2022

Expiration: June 04, 2023

No longer available for credit.

Share

Faculty

Julie M. Vose

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Genmab US

Incyte Corporation

Lilly

Program Director Disclosure

Program Director

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Daiichi Sankyo, Genentech, Janssen, Lilly, and MEI Pharma.